UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT
Pursuant To Section 13 OR 15(d) of
The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): May 11, 2018

DELMAR PHARMACEUTICALS, INC.
(Exact name of registrant as specified in its charter)

Nevada	**001-37823**	**99-0360497**
(State or other jurisdiction of incorporation)	(Commission File Number)	(I.R.S. Employer Identification Number)

Suite 720-999 West Broadway
Vancouver, British Columbia
Canada V5Z 1K5
(Address of principal executive offices) (Zip Code)

(604) 629-5989
(Registrant's telephone number, including area code)

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 7.01. Regulation FD.

On May 11, 2018, DelMar Pharmaceuticals, Inc. (the "Company") used the slides attached hereto as Exhibit 99.1 in connection with management presentations to describe its business and preclinical program.

The information in this Current Report on Form 8-K under Item 7.01, including the information contained in Exhibit 99.1, is being furnished to the Securities and Exchange Commission, and shall not be deemed to be "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934 or otherwise subject to the liabilities of that section, and shall not be deemed to be incorporated by reference into any filing under the Securities Act of 1933 or the Securities Exchange Act of 1934, except as shall be expressly set forth by a specific reference in such filing.

Item 9.01. Financial Statements and Exhibits.

(d) The following exhibit is furnished with this report:

Exhibit No.	Description
99.1	Investor Presentation.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

DELMAR PHARMACEUTICALS, INC.

Dated: May 11, 2018

By: */s/ Scott Praill*
Name: Scott Praill
Title: Chief Financial Officer

EXHIBIT INDEX

Exhibit No.	Description
99.1	Investor Presentation.

Exhibit 99.1


Dianhydrogalactitol (VAL-083) reduces glioblastoma tumor progression *in vivo*, upon bevacizumab-induced hypoxia
Anne Steino, Ph.D.
Director, Preclinical Research
CNO, Banff, AB
May 11, 2018
DelMar PHARMACEUTICALS
LUXEMBOURG INSTITUTE OF HEALTH
RESEARCH DEDICATED TO LIFE
NASDAQ: DMPI
Breakthrough Cancer Therapeutics

VAL-083



DelMar PHARMACEUTICALS

VAL-083's novel mechanism of action distinct from TMZ or nitrosoureas



Crosslinks at N^7 guanine, triggering DNA double strand breaks and cell-cycle arrest in S/G2

Temozolomide & nitrosoureas

Methylation at O^6 position of guanine is readily repaired by MGMT, leading to treatment resistance



DelMar PHARMACEUTICALS

GBM

- DelMar Phase I/II clinical trial
  - recurrent GBM, post-TMZ and post-bevacizumab failure
- Well-tolerated dosing regimen for VAL-083
- Trend towards clinical benefit
- Second-line Avastin treatment → Unchanged survival but improved quality of life
- VAL-083 combination with Avastin???
  - providing OS benefit in addition to improved quality of life
  - Hypoxia advantage

DelMar PHARMACEUTICALS

Angiogenesis inhibitor combination

- Avastin-treatment → Increased hypoxia
- Hypoxia → GLUT1/3 upregulation, particularly on CSCs



DelMar PHARMACEUTICALS

Angiogenesis inhibitor combination

- Avastin-treatment → Increased hypoxia
- Hypoxia → GLUT1/3 upregulation, particularly on CSCs
- Monosaccharide backbone
- Readily crosses BBB
- Accumulates in brain tumor tissue
- Potent activity against GBM CSCs



DelMar PHARMACEUTICALS

Angiogenesis inhibitor combination

- Avastin-treatment → Increased hypoxia
- Hypoxia → GLUT1/3 upregulation, particularly on CSCs
- Monosaccharide backbone
- Readily crosses BBB
- Accumulates in brain tumor tissue
- Potent activity against GBM CSCs



DelMar PHARMACEUTICALS

Patient Derived Orthotopic xenograft (PDOX) model of glioblastoma



T16 GBM
Patient biopsy





Organotypic spheroids (max 14d culture)

T16 GBM spheroids orthotopically implanted into Swiss nude mice

- T16 xenografts are **MGMT unmethylated** and highly **TMZ-resistant**.
- Xenograft tumors contain **25% CD133+** cells.
- Avastin treatment leads to **hypoxia** and increased glucose consumption in T16 PDOX model.

Niclou et al. FASEB J 2008
Golebiewska et al. BRAIN 2013
Stieber&Golebiewska et al. Acta Neuropathologica 2014
Bougnaud et al. Oncotarget 2016

DelMar PHARMACEUTICALS

Study design

Groups:
A. Control
B. 20mg/kg Avastin (1 x week)
C. 3.5mg/kg VAL-083 (3 x week)
D. 20mg/kg Avastin (1 x week) + 3.5mg/kg VAL-083 (3 x week)



DelMar PHARMACEUTICALS

Results – tumor volume



MRI T2 evaluation of tumor volumes at day 56.

DelMar PHARMACEUTICALS

Results – tumor volume

Day 49



Day 56



	MRI day 35	MRI day 49	MRI day 56
Control	2.742	25.007	69.232
Avastin	2.215	21.577	46.407
VAL-083	2.348	8.443	11.781
VAL-083 + Avastin	2.391	5.325	7.049

83%

90%

DelMar PHARMACEUTICALS

Results – tumor volume

Day 49



Day 56



	MRI day 35	MRI day 49	MRI day 56
Control	2.742	25.007	69.232
Avastin	2.215	21.577	46.407
VAL-083	2.348	8.443	11.781
VAL-083 + Avastin	2.391	5.325	7.049

83%

90%

DelMar PHARMACEUTICALS

Results – tumor growth rate



Tumor Growth Rate

100*log (TVf/TV0)/(tf-t0).

	Over entire study (21 days)
Control	6.7%
Avastin	6.3%
VAL-083	3.3%
VAL-083 + Avastin	2.2%

DelMar PHARMACEUTICALS

Results – tumor growth rate



DelMar PHARMACEUTICALS

Conclusion

In this MGMT unmethylated, TMZ-resistant GBM model:

- VAL-083 alone
  - Reduced tumor volume by 83%
  - Significantly slowed down tumor growth rate compared to control and to Avastin alone
- VAL-083 in combination with Avastin
  - Reduced tumor volume by 90%
  - Significantly slowed down tumor growth rate compared to control, Avastin alone and VAL-083 alone

DelMar PHARMACEUTICALS

Luxembourg Institute of Health
Norlux Neuro-Oncology Laboratory
Anais Oudin
Virginie Baus
Anna Golebiewska, PhD
Simone Niclou, PhD, Professor

LUXEMBOURG INSTITUTE OF **HEALTH**
RESEARCH DEDICATED TO LIFE

DelMar PHARMACEUTICALS